Psoriasis Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 9.89 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Psoriasis Drugs Market Analysis
The psoriasis drugs market is expected to register a CAGR of 9.89% during the forecast period, 2022-2027.
The COVID-19 pandemic initially had an adverse impact on the psoriasis market, mainly because of the guidelines published by various regulatory bodies suggesting that patients receiving psoriasis treatment are at more risk of getting infected by COVID-19. In March 2020, the International Psoriasis Council (IPC) recommended physicians to discontinue or postpone the prescription of immunosuppressant medications. However, later in September 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania and 16 other research institutions from the United States and Canada, in collaboration with the National Psoriasis Foundation, created guidelines to care for patients with psoriasis during the coronavirus pandemic. The scientists found no evidence that medical interventions to treat psoriasis and psoriatic arthritis should be interrupted or altered to minimize COVID-19 risks. Such guidelines are expected to augment the market growth pace over the pandemic phase.
An increasing disease burden and demand for psoriasis medicines in emerging economies and the increase in psoriasis research and pipeline drugs are the major factors responsible for the market's growth. Novel drugs with oral administration are opening avenues for needle-averse patients. For instance, in November 2020, Bristol Myers Squibb presented Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in patients with psoriatic arthritis. It is a driving factor for better uptake among patients averse to injectables.
Also, in December 2021, Amgen received the United States Food and Drug Administration approval for Otezla (apremilast) for treating adult patients with plaque psoriasis. In addition, key players in the market are involved in various business strategies, such as product launches, to expand their product portfolios and gain a competitive edge in the market.
Due to the abovementioned factors, the market is expected to register a high growth rate during the forecast period. However, the adverse side effects of most of the existing medications and the high cost of treatment are expected to hamper the market's growth.
Psoriasis Drugs Market Trends
This section covers the major market trends shaping the Psoriasis Drugs Market according to our research experts:
Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period
Interleukin inhibitors are anticipated to witness the fastest growth during the forecast period. The factors aiding interleukin inhibitors are their improved safety and efficacy compared to other classes of psoriasis drugs, consistently leading to increased patient adoption. Major approved antibodies targeting interleukins include Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), and SKYRIZI (Risankizumab) and others.
The approvals of drugs by the regulatory authorities are also contributing to the growth of the segment. For instance, in January 2022, AbbVie received United States Food and Drug Administration approval for SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for treating adults with active psoriatic arthritis (PsA). This systemic inflammatory disease affects the skin and joints and impacts approximately 30% of psoriasis patients.
Additionally, in June 2021, UCB reported that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for recommending, granting, and marketing authorization for BIMZELX (bimekizumab), an investigational IL-17A and IL-17F inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Such approvals and launches are contributing to the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to show significant growth over the forecast period.
North America Dominates the Market and is Expected to do so in the Forecast Period
North America has been one of the worst affected regions by the ongoing COVID-19 pandemic. The growth of the psoriasis market is expected to slow down to some extent because patients avoid visiting dermatology clinics for psoriasis treatment. Apart from restrictions on non-emergency medical services, new rules by the governments across this region have forced several players in the psoriasis drug market to halt their business operations, which has impacted the growth of the market.
However, the region is expected to dominate the psoriasis market during the forecast period due to an increase in disease burden and demand for psoriasis medicines, increasing use of combination therapies, and an upsurge in psoriasis research and pipeline drugs. In North America, the United States holds the largest market share due to the high psoriasis prevalence. As per the article titled "Prevalence of Psoriasis in Children and Adolescents in the United States" published in the JAMA Network 2021, an estimated 7.55 million United States adults were living with psoriasis. Psoriasis prevalence was similar between women and men, with 3.2% in women and 2.8% in men. Other factors that will propel the market's growth include the presence of favorable government initiatives and the presence of developed healthcare infrastructure.
Moreover, MC2 Therapeutics, a Europe-based company, collaborated with EPI Health LLC in August 2020 to commercialize its WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the United States. The WYNZORA Cream was approved in July 2020 by the US FDA for the topical indication of plaque psoriasis in adults. The upcoming launch of WYNZORA Cream in the North American market may further propel the market's growth in this region.
As a result of the aforementioned factors, the market's growth in the region is expected to accelerate over the forecast period.
Psoriasis Drugs Industry Overview
The psoriasis drugs market is moderately competitive and consists of several key players. Concerning the market share, few of the key players currently dominate the market. Companies are focusing on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions, to develop novel products. Some of the major players operating in the market include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr. Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS, Merck and Co. Inc., Novartis AG and Pfizer Inc. among others.
Psoriasis Drugs Market Leaders
-
Eli Lilly and Company
-
Pfizer Inc.
-
Johnson and Johnson (Janssen Global Services, LLC)
-
Novartis AG
-
Amgen Inc.
*Disclaimer: Major Players sorted in no particular order
Psoriasis Drugs Market News
- In July 2022, Arcutis Biotherapeutics, Inc. received the United States Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older.
- In May 2022, Dermavant Sciences received United States Food and Drug Administration (FDA) approval for VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.
Psoriasis Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in Emerging Economies
- 4.2.2 Increasing Use of Combination Therapies
- 4.2.3 Increase in Psoriasis Research and Pipeline Drugs
-
4.3 Market Restraints
- 4.3.1 Adverse Side Effects of Existing Medications
- 4.3.2 High Cost of Psoriasis Treatments
- 4.3.3 Extensive Drug Development and Approval Process
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type of Treatment
- 5.1.1 Biologic Drugs
- 5.1.2 Small Molecule Systemic Drugs
- 5.1.3 Tropical Therapies
-
5.2 By Mechanism of Action
- 5.2.1 TNF Alpha Inhibitors
- 5.2.1.1 Etanercept
- 5.2.1.2 Certolizumab Pegol
- 5.2.1.3 Adalimumab
- 5.2.1.4 Infiximab
- 5.2.1.5 Golimumab
- 5.2.2 PDE4 Inhibitors
- 5.2.2.1 Apremilast
- 5.2.3 Interleukin Inhibitors
- 5.2.3.1 Secukinumab
- 5.2.3.2 Ustekinumab
- 5.2.3.3 Other Interleukin Inhibitors
- 5.2.4 Other Mechanisms of Action
-
5.3 By Route of Administration
- 5.3.1 Oral
- 5.3.2 Parenteral
- 5.3.3 Topical
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Amgen Inc.
- 6.1.3 AstraZenca
- 6.1.4 Biogen Idec
- 6.1.5 Boehringer Ingelheim
- 6.1.6 Celgene Corporation
- 6.1.7 Dr.Reddy`s Laboratories
- 6.1.8 Eli Lilly and Company
- 6.1.9 Forward Pharma
- 6.1.10 Johnson and Johnson (Janssen Biotech Inc.)
- 6.1.11 Leo Pharma AS
- 6.1.12 Merck and Co. Inc.
- 6.1.13 Novartis AG
- 6.1.14 Pfizer Inc.
- 6.1.15 Stiefel Laboratories Inc.
- 6.1.16 Sunpharmaceutical Industries Limited
- 6.1.17 Takeda Pharmaceutical Company Limited
- 6.1.18 UCB SA
- 6.1.19 Valeant Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPsoriasis Drugs Industry Segmentation
As per the scope of the report, psoriasis is a genetic condition that may or may not be present at birth but can also be triggered by certain environmental and genetic factors. Factors such as the changing lifestyles of people and their increased inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people more prone to this condition. The psoriasis drugs market is segmented by type of treatment (biologic drugs, small molecule systemic drugs, and tropical therapies), mechanism of action (TNF alpha inhibitors, PDE4 inhibitors, interleukin inhibitors, and other mechanisms of action), route of administration (oral, parenteral, and topical), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Type of Treatment | Biologic Drugs | |
| Small Molecule Systemic Drugs | ||
| Tropical Therapies | ||
| By Mechanism of Action | TNF Alpha Inhibitors | Etanercept |
| Certolizumab Pegol | ||
| Adalimumab | ||
| Infiximab | ||
| Golimumab | ||
| By Mechanism of Action | PDE4 Inhibitors | Apremilast |
| By Mechanism of Action | Interleukin Inhibitors | Secukinumab |
| Ustekinumab | ||
| Other Interleukin Inhibitors | ||
| By Mechanism of Action | Other Mechanisms of Action | |
| By Route of Administration | Oral | |
| Parenteral | ||
| Topical | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Psoriasis Drugs Market Research FAQs
What is the current Global Psoriasis Drugs Market size?
The Global Psoriasis Drugs Market is projected to register a CAGR of 9.89% during the forecast period (2024-2029)
Who are the key players in Global Psoriasis Drugs Market?
Eli Lilly and Company, Pfizer Inc., Johnson and Johnson (Janssen Global Services, LLC), Novartis AG and Amgen Inc. are the major companies operating in the Global Psoriasis Drugs Market.
Which is the fastest growing region in Global Psoriasis Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Psoriasis Drugs Market?
In 2024, the North America accounts for the largest market share in Global Psoriasis Drugs Market.
What years does this Global Psoriasis Drugs Market cover?
The report covers the Global Psoriasis Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Psoriasis Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Psoriasis Drugs Industry Report
Statistics for the 2024 Global Psoriasis Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Psoriasis Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
